Format

Send to

Choose Destination
Cardiovasc Res. 2014 Dec 1;104(3):399-411. doi: 10.1093/cvr/cvu225. Epub 2014 Oct 24.

ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies.

Author information

1
Hatter Institute for Cardiovascular Research in Africa and MRC Inter-University Cape Heart Group, University of Cape Town, Cape Town, South Africa.
2
Department of Cardiology, Aarhus University Hospital Skejby, Aarhus N, Denmark.
3
Humanitas Clinical and Research Institute, National Research Council of Italy, Rozzano, Italy.
4
The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews.
5
Department of Cardiology, Vall d'Hebron University Hospital and Research Institute, Universitat Autónoma de Barcelona, Barcelona, Spain.
6
Experimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
7
Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary Pharmahungary Group, Szeged, Hungary.
8
Institut für Pathophysiologie, West German Heart and Vascular Centre, Universitätsklinikum Essen, Essen, Germany.
9
Institute of Cardiology and Center of Excellence on Aging, 'G. d'Annunzio' University of Chieti, Chieti, Italy Texas Heart Institute, Houston, TX, USA Department of Internal Medicine, University of Texas Medical School, Center of Cardiovascular and Atherosclerosis Research, Houston, TX, USA.
10
Inserm U 1060 (CarMeN_Cardioprotection Team) & CIC de Lyon, Service d'Exploration Fonctionnelles Cardiovasculaires, Hospices Civils de Lyon, Université Claude Bernard Lyon1, Lyon, France.
11
Justus Liebig University Giessen, Giessen, Germany.
12
University Medical Center Utrecht, Utrecht, the Netherlands.
13
University Medical Center Utrecht and Hubrecht Institute, Utrecht, the Netherlands.
14
The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews d.hausenloy@ucl.ac.uk.

Abstract

Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.

KEYWORDS:

Animal models; Cardioprotection; Ischaemia; Myocardial infarction; Reperfusion

PMID:
25344369
PMCID:
PMC4242141
DOI:
10.1093/cvr/cvu225
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center